Cardiac Marker Testing Market by Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemiluminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing (Lab, POC) - Global Forecast to 2021
The global cardiac marker testing market is projected to reach USD 3.50 Billion by 2021, at a CAGR of 8.8% in the forecast period (2016–2021). Factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the market. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are some of the key factors hampering the growth of this market.
Emerging markets, including India and China, have become attractive destinations for companies engaged in the development and marketing of cardiac biomarkers. Rising prevalence and incidence of cardiovascular diseases is among the major driving factors for the growth of this market in China and India. For instance, annual cardiovascular events in China were projected to increase by more than 50% from 2010 to 2030. China has one of the highest CVD death rates in the world and it is estimated that one in 5 adults in China has a cardiovascular disease (Source: American Heart Association). In addition to this, public–private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars are the key factors propelling the demand for cardiac biomarkers in the emerging markets.
As of 2016, Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), and Siemens AG (Germany) held the leadership position in the global cardiac marker testing market. In the past three years, these companies adopted product launches, product showcase, agreements, and partnerships as their key business strategies to ensure market dominance. Danaher Corporation (U.S.) Alere, Inc. (U.S.), bioMérieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (U.S.), Randox laboratories Ltd (U.K.), and Guangzhou Wondfo Biotech Co., Ltd. (China) are some of the other players in this market.
Stakeholders
- Biomarkers assays and reagents manufacturers, vendors, and distributors
- Contract research organizations (CROs)
- Diagnostic kit manufacturing companies
- Imaging instrument providers
- Market research and consulting firms
- Pharmaceutical companies
To know about the assumptions considered for the study, download the pdf brochure
Scope of the Report
This report categorizes the global cardiac marker testing market into the following segments and subsegments:
Global Cardiac Marker Testing Market, by Type
- Troponin I and T
- CK-MB
- Myoglobin
- Brain Natriuretic Peptide (BNP) or NT-proBNP
- C-reactive Protein (hsCRP)
- Other Biomarkers (galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine)
Global Cardiac Marker Testing Market, by Product
- Instruments
- Chemiluminescence
- Immunofluorescence
- ELISA
- Immunochromatography
- Reagents and Kits
Global Cardiac Marker Testing Market, by Disease
- Myocardial Infarction
- Congestive Heart Failure
Global Cardiac Marker Testing Market, by Type of Testing
- Laboratory Testing
- Point-of-care Testing
Global Cardiac Marker Testing Market, by Region
- North America
- U.S.
- Canada
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the cardiac marker testing market into North America, Europe, Asia-Pacific, and the RoW
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
The cardiac marker testing market is expected to reach ~USD 3.50 Billion by 2021 from USD 2.30 Billion in 2016, at a CAGR of 8.8% between 2016 and 2021. Factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for identification of novel cardiac biomarkers are propelling the growth of the global market. However, technical problems related to sample collection and storage and issues related to regulatory and reimburse systems are some of the major factors restraining the growth of this market.
On the basis of type, the global cardiac marker testing market is segmented into troponin I and T, CK-MB, BNP or NT-proBNP, Myoglobin, hsCRP, and other biomarkers. The other biomarkers segment comprises galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine. The troponin I and T segment is expected to grow at the highest CAGR owing to the high sensitivity and specificity, longer elevation time, and rapid prediction of outcomes or mortality.
On the basis of product, the global market has been divided into two segments, namely, reagents and kits and instruments. The instruments section is further segmented on the basis of method, namely, chemiluminescence, immunofluorescence, ELISA, and immunochromatography. The reagents and kits segment is expected to grow at the highest CAGR during the forecast period. Increasing number of cardiac biomarker tests performed due to the growing aging population and burden of cardiovascular diseases, availability of various reagents and kits, and the continuous launch of new, faster, and reliable products is contributing to the high growth of this market segment.
The global cardiac marker testing technology market is segmented on the basis of type of testing into laboratory testing and point-of-care testing. The point-of-care testing segment is the fastest-growing segment in this market owing to the advantages offered by it (such as reductions in length of stay, improved emergency department efficiency, increased patient satisfaction and user experience, better turnaround times, and simpler sample collection method versus that in central lab testing), rising hospital point-of-care (POC) testing procedures, and technological advancements with regard to the development of advanced, faster, and easy-to-use devices.
Based on disease, the market is segmented into myocardial infarction and congestive heart failure. The myocardial infarction segment is expected to account for the largest share of the global cardiac marker testing market in 2016, and is expected to grow at the highest CAGR during the forecast period. The large share and high growth in this segment can be attributed to the increasing number of patients requiring investigation for diagnosis of acute myocardial infarction in emergency departments compared to other cardiac disorders.
North America is expected to account for the largest share of the global cardiac marker testing market in 2016, followed by Europe and Asia-Pacific. The Asia-Pacific market is expected to register the highest CAGR during the forecast period. The high growth in this segment can be attributed to rising prevalence and incidence of cardiovascular diseases, public–private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians, and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars in the region.
The cardiac marker testing market is highly competitive owing to the presence of a number of large and small firms. With improving industry standards, the global market has been witnessing several product innovations. New product launches was the key growth strategy adopted by market players to strengthen their market positions.
The major players in the global cardiac marker testing market are Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.) Alere, Inc. (U.S.), bioMérieux SA (France), LSI Medience Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation, Japan), Ortho Clinical Diagnostics (a subsidiary of The Carlyle Group, U.S.), Randox laboratories Ltd (U.K.), and Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) (China).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 18)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Breakdown of Primaries
2.2.2.2 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Research Methodology: Bottom-Up Approach
2.3.2 Research Methodology: Top-Down Approach
2.4 Market Breakdown and Data Triangulation
3 Executive Summary (Page No. - 26)
3.1 Introduction
3.2 Evolution
3.3 Current Scenario
3.4 Future Outlook
3.5 Conclusion
4 Premium Insights (Page No. - 32)
4.1 Global Cardiac Marker Testing Market Overview
4.2 Geographic Analysis: Cardiac Marker Testing Market, By Technology, 2016
4.3 Market Size, By Type, 2016 vs 2021
4.4 Market, By Product, 2016 vs 2021
4.5 Geographical Snapshot of the Market, 2016
4.6 Life Cycle Analysis, By Region
5 Market Overview (Page No. - 37)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Incidences of Cardiovascular Diseases
5.2.1.2 Rapidly Increasing Geriatric Population and the Subsequent Increase in the Burden of Heart Diseases Worldwide
5.2.1.3 Growing Funding From Public–Private Organizations for Research on Cardiac Biomarkers
5.2.1.4 Ongoing Clinical Trials for Identification of Novel Cardiac Biomarkers
5.2.2 Restraints
5.2.2.1 Technical Problems Related to Sample Collection and Storage
5.2.2.2 Issues Related to Regulatory and Reimbursement Systems
5.2.3 Opportunities
5.2.3.1 Point-Of-Care Testing (Poct) With Cardiac Biomarkers
5.2.3.2 Emerging Markets to Offer New Growth Avenues for Market Players
6 Industry Insights (Page No. - 44)
6.1 Introduction
6.2 Value Chain Analysis
6.3 Industry Trends
6.3.1 Ongoing Research on Novel Cardiac Biomarkers for Cardiovascular Diseases
6.3.2 Combination of Various Cardiac Biomarkers to Improve Patient Management
6.3.3 Development of High-Sensitivity Troponin Assays
6.4 Porter’s Five Forces Analysis
6.4.1 Threat of New Entrants
6.4.2 Threat of Substitutes
6.4.3 Bargaining Power of Suppliers
6.4.4 Bargaining Power of Buyers
6.4.5 Intensity of Competitive Rivalry
7 Cardiac Marker Testing Market, By Type (Page No. - 52)
7.1 Introduction
7.2 Troponin I and T
7.3 CK-MB
7.4 Bnp Or Nt-Probnp
7.5 Myoglobin
7.6 Hscrp
7.7 Other Biomarkers
8 Cardiac Marker Testing Market, By Product (Page No. - 65)
8.1 Introduction
8.2 Reagents and Kits
8.3 Instruments
8.3.1 Chemiluminescence
8.3.2 Immunofluorescence
8.3.3 Elisa
8.3.4 Immunochromatography
9 Cardiac Marker Testing Market, By Disease (Page No. - 77)
9.1 Introduction
9.2 Myocardial Infarction
9.3 Congestive Heart Failure
10 Cardiac Marker Testing Market, By Type of Testing (Page No. - 83)
10.1 Introduction
10.2 Laboratory Testing
10.3 Point-Of-Care Testing
11 Cardiac Marker Testing Market, By Region (Page No. - 89)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.1.1 Growing Prevalence of Cardiovascular Diseases
11.2.1.2 Increasing Public-Private Investments on Cardiac Biomarker Research
11.2.1.3 Rising Geriatric & Obese Population
11.2.1.4 Nih Support for the Development of Cardiac Biomarkers
11.2.2 Canada
11.2.2.1 Rising Incidence of Cardiovascular Diseases
11.2.2.2 Increasing Government Investments
11.3 Europe
11.3.1 Rising Incidence of CVD
11.3.2 Increasing Number of Conferences and Symposiums
11.3.3 Rising Partnerships and Collaborations for the Development of Cardiac Biomarkers
11.3.4 Increasing Government Investments to Develop Novel Cardiac Biomarkers
11.4 Asia-Pacific
11.4.1 Increasing Incidence of CVD
11.4.2 Increasing Awareness Due to Going Conferences and Initiatives Taken By Market Players
11.4.3 Government Investments Towards Cardiac Biomarker Research
11.5 Rest of the World
12 Competitive Landscape (Page No. - 114)
12.1 Introduction
12.2 Strategic Overview
12.3 Leading Players in the Market
12.4 Competitive Situation and Trends
12.4.1 Product Launches, Approvals, and Showcases
12.4.2 Agreements and Partnerships
12.4.3 Acquisitions
12.4.4 Other Developments
13 Company Profiles (Page No. - 120)
(Overview, Products and Services, Financials, Strategy & Development)*
13.1 Introduction
13.2 Roche Diagnostics Limited (A Subsidiary of F. Hoffman-LA Roche Ltd.)
13.3 Abbott Laboratories
13.4 Siemens AG
13.5 Danaher Corporation
13.6 Biomérieux SA
13.7 Alere Inc.
13.8 LSI Medience Corporation (A Subsidiary 0f Mitsubishi Chemical Holdings Corporation)
13.9 Ortho Clinical Diagnostics (A Subsidiary of the Carlyle Group)
13.10 Randox Laboratories Ltd.
13.11 Guangzhou Wondfo Biotech Co., Ltd.
*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.
14 Appendix (Page No. - 140)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.4 Introducing RT: Real-Time Market Intelligence
14.5 Available Customizations
14.6 Related Reports
List of Tables (71 Tables)
Table 1 Cardiac Marker Testing Market Size, By Type, 2014–2021 (USD Million)
Table 2 Characteristics of Troponin Cardiac Marker
Table 3 Market Size for Troponin I and T, By Region, 2014–2021 (USD Million)
Table 4 North America: Market Size Troponin I and T, By Country, 2014–2021 (USD Million)
Table 5 Characteristics of CK-MB Cardiac Marker
Table 6 Market Size for CK-MB, By Region, 2014–2021 (USD Million)
Table 7 North America: Market Size CK-MB, By Country, 2014–2021 (USD Million)
Table 8 Market Size for Bnp Or Nt-Probnp, By Region, 2014–2021 (USD Million)
Table 9 North America: Market Size Bnp Or Nt-Probnp, By Country, 2014–2021 (USD Million)
Table 10 Characteristics of Myoglobin Cardiac Marker
Table 11 Market Size for Myoglobin, By Region, 2014–2021 (USD Million)
Table 12 North America: Market Size for Myoglobin, By Country, 2014–2021 (USD Million)
Table 13 Cut-Offs for CRP Using Standardized Assay
Table 14 Market Size for Hscrp, By Region, 2014–2021 (USD Million)
Table 15 North America: Market Size for Hscrp, By Country, 2014–2021 (USD Million)
Table 16 Market Size for Other Biomarkers, By Region, 2014–2021 (USD Million)
Table 17 North America: Market Size for Other Biomarkers, By Country, 2014–2021 (USD Million)
Table 18 Market Size, By Product, 2014–2021 (USD Million)
Table 19 Cardiac Marker Testing Reagents and Kits Market Size, By Region, 2014–2021 (USD Million)
Table 20 North America: Cardiac Marker Testing Reagents & Kits Market Size, By Country, 2014–2021 (USD Million)
Table 21 Cardiac Marker Testing Instruments Market Size, By Region, 2014–2021 (USD Million)
Table 22 North America: Cardiac Marker Testing Instruments Market Size, By Country, 2014–2021 (USD Million)
Table 23 Cardiac Marker Testing Instruments Market Size, By Method, 2014–2021 (USD Million)
Table 24 Cardiac Marker Testing Instruments Market Size for Chemiluminescence, By Region, 2014–2021 (USD Million)
Table 25 North America: Cardiac Marker Testing Instruments Market Size for Chemiluminescence, By Country, 2014–2021 (USD Million)
Table 26 Cardiac Marker Testing Instruments Market Size for Immunofluorescence, By Region, 2014–2021 (USD Million)
Table 27 North America: Cardiac Marker Testing Instruments Market Size for Immunofluorescence, By Country, 2014–2021 (USD Million)
Table 28 Cardiac Marker Testing Instruments Market Size for Elisa, By Region, 2014–2021 (USD Million)
Table 29 North America: Cardiac Marker Testing Instruments Market Size for Elisa, By Country, 2014–2021 (USD Million)
Table 30 Cardiac Marker Testing Instruments Market Size for Immunochromatography, By Region, 2014–2021 (USD Million)
Table 31 North America: Cardiac Marker Testing Instruments Market Size for Immunochromatography, By Country, 2014–2021 (USD Million)
Table 32 Market Size, By Disease, 2014–2021 (USD Million)
Table 33 Market Size for Myocardial Infarction, By Region, 2014–2021 (USD Million)
Table 34 North America: Market Size for Myocardial Infarction, By Country, 2014–2021 (USD Million)
Table 35 Market Size for Congestive Heart Failure, By Region, 2014–2021 (USD Million)
Table 36 North America: Market Size for Congestive Heart Failure, By Country, 2014–2021 (USD Million)
Table 37 Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 38 Cardiac Marker Laboratory Testing Market Size, By Region, 2014–2021 (USD Million)
Table 39 North America: Cardiac Marker Laboratory Testing Market Size, By Country, 2014–2021 (USD Million)
Table 40 Cardiac Marker Point-Of-Care Testing Market Size, By Region, 2014–2021 (USD Million)
Table 41 North America: Cardiac Marker Point-Of-Care Testing Market Size, By Country, 2014–2021 (USD Million)
Table 42 Market Size, By Region, 2014-2021 (USD Million)
Table 43 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 44 North America: Market Size, By Type, 2014–2021 (USD Million)
Table 45 North America: Market Size, By Product, 2014–2021 (USD Million)
Table 46 North America: Market Size, By Disease, 2014–2021 (USD Million)
Table 47 North America: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 48 U.S.: Market Size, By Type, 2014–2021 (USD Million)
Table 49 U.S.: Market Size, By Product, 2014–2021 (USD Million)
Table 50 U.S.: Market Size, By Disease, 2014–2021 (USD Million)
Table 51 U.S.: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 52 Canada: Market Size, By Type, 2014–2021 (USD Million)
Table 53 Canada: Market Size, By Product, 2014–2021 (USD Million)
Table 54 Canada: Market Size, By Disease, 2014–2021 (USD Million)
Table 55 Canada: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 56 Europe: Market Size, By Type, 2014–2021 (USD Million)
Table 57 Europe: Market Size, By Product, 2014–2021 (USD Million)
Table 58 Europe: Market Size, By Disease, 2014–2021 (USD Million)
Table 59 Europe: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 60 Asia-Pacific: Market Size, By Type, 2014–2021 (USD Million)
Table 61 Asia-Pacific: Market Size, By Product, 2014–2021 (USD Million)
Table 62 Asia-Pacific: Market Size, By Disease, 2014–2021 (USD Million)
Table 63 Asia-Pacific: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 64 RoW: Market Size, By Type, 2014–2021 (USD Million)
Table 65 RoW: Market Size, By Product, 2014–2021 (USD Million)
Table 66 RoW: Market Size, By Disease, 2014–2021 (USD Million)
Table 67 RoW: Market Size, By Type of Testing, 2014–2021 (USD Million)
Table 68 Product Launches, Approvals, and Showcases, 2013–2016
Table 69 Agreements and Partnerships, 2013-2016
Table 70 Acquisitions, 2013–2016
Table 71 Other Developments, 2013–2016
List of Figures (44 Figures)
Figure 1 Global Cardiac Marker Testing Market: Research Methodology Steps
Figure 2 Breakdown of Supply-Side Primary Interviews: By Company Type, Designation, and Region
Figure 3 Research Design
Figure 4 Market: Data Triangulation
Figure 5 Evolution of Cardiac Biomarkers
Figure 6 Market Size, By Type, 2016 vs 2021 (USD Million)
Figure 7 Global Market Size, By Product, 2016 vs 2021 (USD Million)
Figure 8 Global Market Size, By Disease, 2016 vs 2021 (USD Million)
Figure 9 Global Market Size, By Type of Testing, 2016 vs 2021 (USD Million)
Figure 10 Global Market, By Region, 2016
Figure 11 Increasing Incidences of Cardiovascular Diseases Across the Globe are Driving Growth in the Market
Figure 12 Troponin I and T to Dominate the Market in 2016
Figure 13 Reagents and Kits to Continue to Dominate the Market During the Forecast Period
Figure 14 Asia-Pacific to Witness Highest Growth During the Forecast Period
Figure 15 Asia-Pacific Holds Lucrative Growth Opportunities
Figure 16 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Market: Value Chain Analysis
Figure 18 Porter’s Five Forces Analysis 2016
Figure 19 Market Segmentation, By Type
Figure 20 Market Size, By Type, 2016-2021
Figure 21 Market Segmentation, By Product
Figure 22 Market Size, By Product, 2016 (USD Million)
Figure 23 Cardiac Marker Testing Market Segmentation, By Disease
Figure 24 Cardiac Marker Testing Market Size, By Disease, 2016 (USD Million)
Figure 25 Prevalence of Congestive Heart Failure, 2014
Figure 26 Cardiac Marker Testing Market Segmentation, By Type of Testing
Figure 27 Cardiac Marker Testing Market Size, By Type of Testing, 2016 (USD Million)
Figure 28 Cardiac Marker Testing Market, By Region
Figure 29 Asia-Pacific to Grow at the Highest Rate During the Forecast Period
Figure 30 North America: Cardiac Marker Testing Market Snapshot
Figure 31 Europe: Cardiac Marker Testing Market Snapshot
Figure 32 Asia-Pacific: Cardiac Marker Testing Market Snapshot
Figure 33 RoW: Cardiac Marker Testing Market Snapshot
Figure 34 Key Growth Strategies Adopted By Market Players From 2013 to 2016
Figure 35 Rank of Key Players in the Global Cardiac Marker Testing Market, 2015
Figure 36 Product Launches and Showcases—Majorly Adopted Growth Strategy By Market Players From 2013 to 2016
Figure 37 Financial Performance of the Top 6 Market Players in 2015
Figure 38 Roche Diagnostics Limited: Company Snapshot
Figure 39 Abbott Laboratories: Company Snapshot
Figure 40 Siemens AG: Company Snapshot
Figure 41 Danaher Corporation: Company Snapshot
Figure 42 Biomérieux SA: Company Snapshot
Figure 43 Alere Inc.: Company Snapshot
Figure 44 Mitsubishi Chemical Holdings Corporation: Company Snapshot
Get in-depth analysis of the COVID-19 impact on the Cardiac Marker Testing Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Cardiac Marker Testing Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cardiac Marker Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Cardiac Marker Testing Market